Abstract:To investigate the antitumor mechanism of MAP30 in human bladder cell line (T24) and its potential toxic effects in mice. In this study, the biological behavior of MAP30's influence on bladder cell was investigated to reveal the antitumor mechanism and role of MAP30 in bladder cancer. MAP30 gene sequence optimized by gene synthesis codon was inserted into the prokaryotic expression vector pET-28a to produce a large amount of target protein in Escherichia coli. The protein product was obtained after purification. Membrane hydration method was used to prepare MAP30 liposome in order to enhance its membrane permeability. The effects of MAP30 on the viability, apoptosis and migration of T24 cell were assessed using 3"‘(4,5"‘dimethyl"‘thiazol"‘2"‘yl)"‘2,5"‘diphenyl"‘2H"‘tetrazolium bromide (MTT), flow cytometric and TUNEL assays, respectively. Mice were transfected with bladder cancer cells for 48 h. The expressions of apoptotic and non-apoptotic proteins were determined using Western blotting. Changes in tumor volume and occurrence of metastasis were assessed using luciferase assay. After 7 days, liver and kidney were excised for histological examination. The levels of reactive oxygen species (ROS), malondialdehyde (MDA), and reduced glutathione (GSH), and activities of catalase and glutathione peroxidase (GPx) were determined in serum or homogenate using enzyme-linked immunosorbent assay (ELISA). The yield of MAP30 after purification was significantly increased. The results of MTT assay showed that MAP30 significantly and concentration-dependently inhibited the proliferation and migration of T24 cells (p < 0.05). The prepared liposomes had uniform hydrated particle size of 132.6 nm, with encapsulation efficiency of 78 %. The inhibitory effect of MAP30 liposome on T24 cells was significantly higher than that of MAP30, and MAP30 significantly increased the number of apoptotic cells (p < 0.05). Western blotting showed that MAP30 significantly promoted the expression of caspase 3 (p < 0.05), but did not significantly affect the expressions of bcl-2 and bax (p > 0.05). It also significantly down-regulated the expressions of NF-kB, JNK and MMP2 (p < 0.05). Tumor formation was significantly inhibited, and tumor volume reduced in bladder cancer-bearing mice after treatment with MAP30 (p < 0.05). Histological examination showed that MAP30 induced mild histological changes in the liver and kidney of mice, and significantly increased the level of MDA at day 1 (p < 0.05). It also significantly and time-dependently increased ROS, but reduced GSH levels and activities of catalase and GPx (p < 0.05). However, MAP30 had no significant effect on DNA (p > 0.05). The apoptotic effect of MAP30 in T24 cells is mediated via activation of caspase-3 signaling pathway. The protein produces mild histological changes in the liver and kidney of mice, but has no significant effect on DNA.

Enhanced Anticancer Effect of MAP30–S3 by Cyclosproin A Through Endosomal Escape

Methionine Enkephalin Activates Autophagy and Stimulates Tumour Cell Immunogenicity in Human Cutaneous Squamous Cell Carcinoma

Raddeanin A synergistically enhances the anti-tumor effect of MAP30 in multiple ways, more than promoting endosomal escape

Recombinant Expression and Purification of a MAP30-cell Penetrating Peptide Fusion Protein with Higher Anti-Tumor Bioactivity.

In Situ Proapoptotic Peptide-Generating Rapeseed Protein-Based Nanocomplexes Synergize Chemotherapy for Cathepsin-B Overexpressing Breast Cancer.

A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer

Cytotoxic effects of recombinant proteins enhanced by momordin Ic are dependent on cholesterol and ganglioside GM1

Saponin and Ribosome-Inactivating Protein Synergistically Trigger Lysosome-Dependent Apoptosis by Inhibiting Lysophagy: Potential to Become a New Antitumor Strategy

MAP30 protein from <i>Momordica charantia</i> is therapeutic and has synergic activity with cisplatin against ovarian cancer <i>in vivo</i> by altering metabolism and inducing ferroptosis

Antitumor Mechanism of MAP30 in Bladder Cancer T24 Cells, and Its Potential Toxic Effects in Mice.

Enhanced Anti-Tumor Activity of Trichosanthin after Combination with a Human-Derived Cell-Penetrating Peptide, and a Possible Mechanism of Activity

Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity

MAP30 Promotes Apoptosis of U251 and U87 Cells by Suppressing the LGR5 and Wnt/β-catenin Signaling Pathway, and Enhancing Smac Expression.

The Effect of Cyclosporine A on Proteins Controlling Intracellular Calcium Concentration in Breast Cancer Cells

Application of EGF-like Growth Factor-derived Tumor-homing Peptide for Antineoplastic Protein

Expression of Momordica Charantia MAP30 and Its Antitumor Effect on Bladder Cancer Cells

In addition to its endosomal escape effect, platycodin D also synergizes with ribosomal inactivation protein to induce apoptosis in hepatoma cells through AKT and MAPK signaling pathways

Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway

Chondroitin sulfate-modified antiangiogenic peptide conjugate induces cell apoptosis via the mitochondria-mediated pathway to perform antitumor activity

Effects of Over-Expressed Smac Gene Coupling with Cisplatin on Proliferation and Apoptosis of Hepatocarcinoma Cells

Enhancing Tumor-Specific Intracellular Delivering Efficiency of Cell-Penetrating Peptide by Fusion with a Peptide Targeting to EGFR